Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.02
(-12.0%)
HKD 0.02
(-12.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -28.84 Million HKD | 73.72% |
| 2022 | -109.74 Million HKD | -2310.37% |
| 2021 | -4.55 Million HKD | 77.33% |
| 2020 | -20.08 Million HKD | -130.8% |
| 2019 | 65.21 Million HKD | 100.66% |
| 2018 | 32.49 Million HKD | 1899.5% |
| 2017 | -1.8 Million HKD | 95.13% |
| 2016 | -37.07 Million HKD | -8.29% |
| 2015 | -34.23 Million HKD | -298.13% |
| 2014 | 17.28 Million HKD | -46.94% |
| 2013 | 32.56 Million HKD | 21.35% |
| 2012 | 26.83 Million HKD | -64.77% |
| 2011 | 76.15 Million HKD | -54.76% |
| 2010 | 168.33 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 4.74 Million HKD | 0.0% |
| 2023 Q1 | 19.56 Million HKD | 288.74% |
| 2023 Q2 | 39.13 Million HKD | 100.0% |
| 2023 FY | -28.84 Million HKD | 73.72% |
| 2023 Q4 | -67.98 Million HKD | -100.0% |
| 2023 Q3 | -33.99 Million HKD | -186.85% |
| 2022 Q1 | -25.57 Million HKD | -142.31% |
| 2022 FY | -109.74 Million HKD | -2310.37% |
| 2022 Q4 | -10.36 Million HKD | 38.51% |
| 2022 Q3 | -16.86 Million HKD | 45.92% |
| 2022 Q2 | -31.17 Million HKD | -21.9% |
| 2021 FY | -4.55 Million HKD | 77.33% |
| 2021 Q1 | -44.59 Million HKD | 79.56% |
| 2021 Q2 | -75.5 Million HKD | -69.32% |
| 2021 Q3 | 30.22 Million HKD | 140.03% |
| 2021 Q4 | 60.45 Million HKD | 100.0% |
| 2020 FY | -20.08 Million HKD | -130.8% |
| 2020 Q1 | -6.42 Million HKD | -110.49% |
| 2020 Q2 | -49 Million HKD | -662.5% |
| 2020 Q4 | -218.15 Million HKD | 0.0% |
| 2019 Q2 | -25.19 Million HKD | -100.0% |
| 2019 Q3 | 30.64 Million HKD | 221.66% |
| 2019 Q1 | -12.59 Million HKD | -153.34% |
| 2019 FY | 65.21 Million HKD | 100.66% |
| 2019 Q4 | 61.29 Million HKD | 100.0% |
| 2018 Q2 | -7.36 Million HKD | 0.0% |
| 2018 Q4 | 23.61 Million HKD | 0.0% |
| 2018 FY | 32.49 Million HKD | 1899.5% |
| 2018 Q1 | -7.36 Million HKD | -324.73% |
| 2018 Q3 | 23.61 Million HKD | 420.62% |
| 2017 Q1 | -4.18 Million HKD | 56.06% |
| 2017 FY | -1.8 Million HKD | 95.13% |
| 2017 Q4 | 3.27 Million HKD | 0.0% |
| 2017 Q3 | 3.27 Million HKD | 178.4% |
| 2017 Q2 | -4.18 Million HKD | 0.0% |
| 2016 Q2 | -9.02 Million HKD | 0.0% |
| 2016 Q4 | -9.51 Million HKD | 0.0% |
| 2016 Q3 | -9.51 Million HKD | -5.44% |
| 2016 Q1 | -9.02 Million HKD | 41.07% |
| 2016 FY | -37.07 Million HKD | -8.29% |
| 2015 Q2 | -1.8 Million HKD | 0.0% |
| 2015 Q3 | -15.31 Million HKD | -747.34% |
| 2015 Q4 | -15.31 Million HKD | 0.0% |
| 2015 FY | -34.23 Million HKD | -298.13% |
| 2015 Q1 | -1.8 Million HKD | -274.93% |
| 2014 Q3 | 1.03 Million HKD | -86.42% |
| 2014 Q4 | 1.03 Million HKD | 0.0% |
| 2014 Q2 | 7.6 Million HKD | 0.0% |
| 2014 Q1 | 7.6 Million HKD | -32.45% |
| 2014 FY | 17.28 Million HKD | -46.94% |
| 2013 Q3 | 11.26 Million HKD | 124.25% |
| 2013 FY | 32.56 Million HKD | 21.35% |
| 2013 Q1 | 5.02 Million HKD | -17.25% |
| 2013 Q2 | 5.02 Million HKD | 0.0% |
| 2013 Q4 | 11.26 Million HKD | 0.0% |
| 2012 FY | 26.83 Million HKD | -64.77% |
| 2012 Q3 | 6.06 Million HKD | -34.63% |
| 2012 Q2 | 9.28 Million HKD | 0.0% |
| 2012 Q4 | 6.06 Million HKD | 0.0% |
| 2012 Q1 | 9.28 Million HKD | 0.0% |
| 2011 Q2 | 22.12 Million HKD | 0.0% |
| 2011 Q4 | 9.28 Million HKD | -58.04% |
| 2011 FY | 76.15 Million HKD | -54.76% |
| 2011 Q1 | 22.12 Million HKD | 0.0% |
| 2011 Q3 | 22.12 Million HKD | 0.0% |
| 2010 Q4 | 22.12 Million HKD | -76.37% |
| 2010 Q1 | 93.62 Million HKD | 0.0% |
| 2010 Q2 | 93.62 Million HKD | 0.0% |
| 2010 FY | 168.33 Million HKD | 0.0% |
| 2010 Q3 | 93.62 Million HKD | 0.0% |
| 2009 Q4 | 93.62 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 127.459% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 101.534% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 82.299% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -87.829% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 45.275% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 272.733% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 110.478% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 72.81% |
| SSY Group Limited | 1.31 Billion HKD | 102.187% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 122.108% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 110.804% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 100.748% |